galinpepimut-s
galinpepimut-s: sourced relationships with 1 company · 2 clinical trials tracked.
galinpepimut-s evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could galinpepimut-s → SLS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | Phase 3 |
Clinical Trial Registry Records (2)
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Primary endpoint: OS
Frequently asked questions
Which companies have sourced relationships with galinpepimut-s?
galinpepimut-s has dated SEC/FDA relationship records for SELLAS Life Sciences Group, Inc..
How many clinical trials involve galinpepimut-s?
BioSniper tracks 2 clinical trials involving galinpepimut-s.